Location History:
- Jerusalem, IL (1998)
- Rishon LeZion, IL (2000 - 2005)
- Rishon LoZion, IL (2006)
Company Filing History:
4 out of 14 
1 out of 893 
1 out of 5 Years Active: 1998-2006
Title: Innovations by Gary Gellerman in Somatostatin Analogues
Introduction
Gary Gellerman, an accomplished inventor based in Rishon LeZion, Israel, has made significant contributions to the field of pharmaceutical compositions, particularly in the development of somatostatin analogs. With a total of five patents, his work emphasizes enhanced therapeutic utility through innovative peptide design.
Latest Patents
Among his latest patents, Gellerman has focused on "Conformationally constrained backbone cyclized somatostatin analogs." These patents describe novel peptides that possess somatostatin receptor subtype selectivity. The disclosed methods of use involve improved therapeutic compositions that utilize these analogs. Furthermore, Gellerman outlines innovative methods for synthesizing these somatostatin analogs and describes screening methodologies for evaluating their effectiveness. The comprehensive nature of his patents highlights both the pharmaceutical compositions comprising these analogs and the methods for their application.
Career Highlights
Throughout his career, Gellerman has worked with prominent organizations including Peptor Limited and Yissum Research Development Company, associated with the Hebrew University of Jerusalem. His experiences at these companies have contributed to his development of cutting-edge pharmaceutical solutions that aim to tackle various medical challenges.
Collaborations
Gary Gellerman has collaborated with notable colleagues such as Vered Hornik and Michel M. Afargan. These partnerships have facilitated a shared vision of innovation in drug development, enhancing the therapeutic applications of somatostatin analogs.
Conclusion
Gary Gellerman's innovative work in the development of somatostatin analogs demonstrates his significant impact on the pharmaceutical industry. His patents not only contribute to the scientific community's understanding of peptide design but also promise improved therapeutic options for patients. As he continues to push the boundaries of innovation, Gellerman exemplifies the spirit of inventorship in modern medicine.